871727-05-8

Basic information

• Product Name: 6-(tert-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid(SALTDATA: FREE)
• Synonyms: 6-(tert-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid(SALTDATA: FREE);3. 6-[(tert-Butoxy)carbonyl]-6-a7.aspiro[2 5]octane- l -carboxyl ic acid;6-Boc-6-azaspiro[2.5]octane-1-carboxylic Acid;6-Azaspiro[2.5]octane-1,6-dicarboxylic acid, 6-(1,1-dimethylethyl) ester;6-azaspiro[2.5]octane-1-carboxylic acid;6-(tert-butoxycarbonyl)-6-azaspiro[2.5]octane-1,6-dicarboxylic acid;6-[(2-methylpropan-2-yl)oxycarbonyl]-6-azaspiro[2.5]octane-2-carboxylic acid;6-(tert-butoxycarbonyl)-6-azaspiro 2.5 octane-1-carboxylic acid(SALTDATA
• CAS NO: 871727-05-8
• Molecular Formula: C₁₃H₂₁NO₄
• Molecular Weight: 191.65526
• Mol File: 871727-05-8.mol

Chemical Properties

• Boiling Point: 392.1±35.0 °C(Predicted)
• Appearance: /
• Density: 1.20±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.71±0.20(Predicted)
• CAS DataBase Reference: 6-(tert-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid(SALTDATA: FREE)(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(tert-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid(SALTDATA: FREE)(871727-05-8)
• EPA Substance Registry System: 6-(tert-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid(SALTDATA: FREE)(871727-05-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 871727-05-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
6-(tert-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid(SALTDATA: FREE) is used as a key intermediate in the synthesis of pharmaceuticals for its ability to protect functional groups and facilitate complex organic reactions. Its presence in the synthesis process aids in the creation of diverse medicinal compounds with specific therapeutic properties.
Used in Organic Synthesis:
In the field of organic chemistry, 6-(tert-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid(SALTDATA: FREE) is used as a protecting agent for functional groups. This role is crucial in multi-step organic synthesis, where the protection and subsequent deprotection of functional groups allow for selective reactions to occur without unwanted side reactions.
Used in Research and Development:
6-(tert-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid(SALTDATA: FREE) is utilized in research and development settings as a tool to explore new chemical reactions and synthetic pathways. Its unique structure and properties make it an important compound for investigating novel methods in organic synthesis and for the development of new pharmaceutical agents.
Used in the Production of Active Pharmaceutical Ingredients (APIs):
6-(tert-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid(SALTDATA: FREE) is used as a building block in the production of APIs, contributing to the development of new drugs and therapeutic agents. Its role in API synthesis is vital for the pharmaceutical industry, as it enables the creation of effective and targeted treatments for various medical conditions.

Upstream product

• 1242268-17-2 6-(tert-butyl) 1-ethyl 6-azaspiro[2.5]octane-1,6-dicarboxylate 
• 871727-04-7 6-tert-butyl 1-methyl 6-azaspiro[2.5]octane-1,6-dicarboxylate 

Downstream Products

• 1239852-32-4 tert-butyl 1-(benzyloxycarbonylamino)-6-azaspiro[2.5]octane-6-carboxylate 
• 1453272-51-9 tert-butyl 1-[[(1S)-1-phenylethyl]carbamoyl]-6-azaspiro[2.5]octane-6-carboxylate 
• 1160247-14-2 tert-butyl 1-carbamoyl-6-azaspiro[2.5]octane-6-carboxylate 
• 1239852-33-5 benzyl 6-azaspiro[2.5]octan-1-ylcarbamate 
• 1453272-50-8 tert-butyl (1S)-1-[[(1S)-1-phenylethyl]carbamoyl]-6-azaspiro[2.5]octane-6-carboxylate 

Relevant articles and documents

COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES

In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.

GLP-1 Receptor Agonists and Uses Thereof

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

GLP-1 RECEPTOR AGONISTS AND USES THEREOF

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza- benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

HETEROARYL PYRIDONE AND AZA-PYRIDONE AMIDE COMPOUNDS

Heteroaryl pyridone and aza-pyridone amide compounds of Formula (I) are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES

Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors

The triaryl bis-sulfone 1 was modified by converting the aryl A-ring to a piperidine ring. The piperidine ring was further elaborated to a spirocyclopropyl piperidine moiety. The effect on CB2 binding potency, rat calcium channel affinity, and CYP 2C9 inh

CANNABINOID RECEPTOR LIGANDS

Compounds of Formula (I) and/or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions containing such compounds exhibit anti-inflammatory and immunomodulatory activity, and can be effective asCB2 receptor ligands in treating cancer and inflammatory, immunomodulatory or respiratory diseases or conditions.